23 results
8-K/A
EX-99.1
IKT
Inhibikase Therapeutics Inc
2 Apr 24
Departure of Directors or Certain Officers
5:12pm
approval of the Company. The Employee may engage in volunteer, charitable, educational, religious and similar types of activities to the extent
424B3
IKT
Inhibikase Therapeutics Inc
4 Apr 23
Prospectus supplement
4:57pm
-70. Upon completion of the 200 mg healthy volunteer study in March 2023 and if no safety concerns arise, we will include the 200 mg dose in the 201
POS AM
IKT
Inhibikase Therapeutics Inc
31 Mar 23
Prospectus update (post-effective amendment)
4:11pm
45-70. Upon completion of the 200 mg healthy volunteer study in March 2023 and if no safety concerns arise, we will include the 200 mg dose in the 201
PRE 14A
hm6zm6i0qt l3r
21 Apr 22
Preliminary proxy
4:33pm
424B4
098d6ser
17 Jun 21
Prospectus supplement with pricing info
4:31pm
DRS
ltf0r
2 Jun 21
Draft registration statement
12:00am
8-K
EX-99.1
fec85 j157z9iu73u6p
1 Jun 21
Regulation FD Disclosure
7:30am
DEF 14A
ngalrtcrr
30 Apr 21
Definitive proxy
5:20pm
10-K
jcfnmpy4xj9vmbw
31 Mar 21
Annual report
2:14pm
8-K
EX-99.1
ffmbxpqxj qhlg
8 Feb 21
Therapies in Clinical Development to Reverse the Progression of Neurodegeneration in Parkinson’s Disease 1Q 2021 I NVESTOR PRESENTATION IKT
7:01am
424B4
cppmjgrm
28 Dec 20
Prospectus supplement with pricing info
6:04am